Skip to main content

Anthem Biosciences Limited (BOM:544449)

India flag India · Delayed Price · Currency is INR
770.15
+30.65 (4.14%)
At close: Apr 27, 2026
Market Cap 432.30B
Revenue (ttm) 20.02B
Net Income (ttm) 4.85B
Shares Out n/a
EPS (ttm) 8.58
PE Ratio 89.20
Forward PE 64.60
Dividend n/a
Ex-Dividend Date n/a
Volume 39,084
Average Volume 26,233
Open 747.15
Previous Close 739.50
Day's Range 739.20 - 774.50
52-Week Range 579.45 - 873.25
Beta n/a
RSI 68.82
Earnings Date Jun 24, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial... [Read more]

Industry Commercial Physical and Biological Research
Founded 2006
Employees 1,963
Stock Exchange Bombay Stock Exchange
Ticker Symbol 544449
Full Company Profile

Financial Performance

In fiscal year 2025, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.

Financial Statements

News

Anthem Biosciences Transcript: Q3 25/26

Nine-month revenue grew to INR 1,513 crore with strong EBITDA margins above 41%. Management expects mid-teen revenue growth and EBITDA/PAT margins above 20% for FY 2026, supported by robust demand, new product approvals, and capacity expansions.

2 months ago - Transcripts

Anthem Biosciences Transcript: Q2 25/26

Revenue and EBITDA grew strongly in H1 FY2026, driven by CRDMO, with margins at 41.4%. Four new commercial molecules were added, capacity expansions are on track, and management expects continued growth and robust margins for the year.

6 months ago - Transcripts

Anthem Biosciences Transcript: Q1 25/26

Q1 FY 2026 saw 60% year-on-year revenue growth to INR 540 crore, driven by strong CRDMO performance and higher commercial molecule volumes. EBITDA margin was 38%, with steady outlook and ongoing capacity expansions funded by robust net cash.

9 months ago - Transcripts